NCT07204652 Colonoscopic Detection of Phosphorylated Alpha-synuclein for Parkinson's Diagnosis
| NCT ID | NCT07204652 |
| Status | Recruiting |
| Phase | — |
| Sponsor | CND Life Sciences |
| Condition | PARKINSON DISEASE (Disorder) |
| Study Type | OBSERVATIONAL |
| Enrollment | 20 participants |
| Start Date | 2025-09-03 |
| Primary Completion | 2028-09 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 20 participants in total. It began in 2025-09-03 with a primary completion date of 2028-09.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this observational study is to learn whether tissue samples taken from the colon during routine colonoscopy can detect signs of Parkinson's disease. The main question it aims to answer is: Can doctors find a protein called alpha-synuclein in colon tissue samples from people with Parkinson's disease? Currently, Parkinson's disease is diagnosed by observing symptoms like tremors and movement problems, but by then the disease has already progressed significantly. Earlier detection could help doctors start treatment sooner.
Eligibility Criteria
Inclusion Criteria: * Adults 40 to 99 years of age * Patients with a confirmed clinical diagnosis of Parkinson's disease by UKPDS Brain Bank Criteria * Patients who have agreed to undergo a routine colonoscopy as part of their surveillance for colon cancer or exclusion of other gastrointestinal diseases Exclusion Criteria: * Use of anticoagulants (Plavix 75 mg or aspirin up to 325 mg alone is allowed) * History of colon cancer * Recent gastrointestinal illness or surgical procedures * Pregnant or planning to become pregnant before the scheduled colonoscopy * Significant cognitive impairment, as determined by study investigators * Decisionally impaired adults who cannot express understanding that this study is voluntary and for research purposes
Contact & Investigator
Delaram Safarpour, MD, MSCE, FAAN
PRINCIPAL INVESTIGATOR
Oregon Health and Science University
Frequently Asked Questions
Who can join the NCT07204652 clinical trial?
This trial is open to participants of all sexes, aged 40 Years or older, up to 99 Years, studying PARKINSON DISEASE (Disorder). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07204652 currently recruiting?
Yes, NCT07204652 is actively recruiting participants. Contact the research team at armendam@ohsu.edu for enrollment information.
Where is the NCT07204652 trial being conducted?
This trial is being conducted at Portland, United States.
Who is sponsoring the NCT07204652 clinical trial?
NCT07204652 is sponsored by CND Life Sciences. The principal investigator is Delaram Safarpour, MD, MSCE, FAAN at Oregon Health and Science University. The trial plans to enroll 20 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.